Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,657 across all filing types
Latest filing 2021-01-21 Declaration of Voting R…
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
2021年第一次临时股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by Guangdong Huashang Law Firm regarding the 2021 first extraordinary general meeting (EGM) of Shenzhen Salubris Pharmaceuticals Co., Ltd. It discusses the legality of the convening, attendance, voting procedures, and results of the shareholders' meeting. The document does not contain financial statements or management discussion but focuses on the legal compliance and validity of the shareholder meeting and its resolutions. It is not an announcement of voting results but a legal opinion on the meeting's conduct and outcomes. Therefore, it fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it relates to the official validation and legal opinion on the voting results of a shareholders' meeting.
2021-01-21 Chinese
2021年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as the "2021 First Extraordinary General Meeting Resolution Announcement" of Shenzhen Salubris Pharmaceuticals Co., Ltd. It details the convening, attendance, voting procedures, and results of a shareholders' meeting, including specific resolutions passed and voting percentages. It also includes legal opinions confirming the validity of the meeting and resolutions. There is no financial data or report content, but rather an official announcement of the voting results and resolutions from the shareholders' meeting. This matches the definition of a Declaration of Voting Results & Voting Rights Announcement (DVA). The document length is about 3200 characters, consistent with an announcement rather than a full report.
2021-01-21 Chinese
2020年度非公开发行A股股票预案（二次修订稿）
Capital/Financing Update Classification · 95% confidence The document is a detailed plan and proposal for a non-public issuance of A shares by Shenzhen Salubris Pharmaceuticals Co., Ltd. for the year 2020. It includes extensive information about the issuance background, purpose, pricing, number of shares, use of proceeds, approval process, and impact analysis. The document is lengthy (15,000 characters) and contains substantive financial and operational details related to the capital raising activity. It is not a simple announcement or a brief summary but a comprehensive plan and analysis related to a capital financing event. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities.
2021-01-20 Chinese
关于非公开发行股票摊薄即期回报对公司主要财务指标的影响及公司采取措施（二次修订稿）的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding the impact of a non-public stock issuance on the company's immediate earnings dilution and the measures taken to mitigate this impact. It includes detailed assumptions, financial impact calculations, risk warnings, and commitments by the board and controlling shareholders to protect investors. The document references regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange, and discusses the dilution effect on earnings per share and net asset returns due to the new share issuance. It is not a full financial report like an annual or interim report, nor is it a simple announcement of a report publication. It is a detailed disclosure about a capital financing event and its financial impact, including the company's measures to address the dilution risk. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length (6920 characters) and content support this classification with high confidence.
2021-01-20 Chinese
关于非公开发行A股股票预案修订说明的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the revision of a non-public issuance plan of A shares by Shenzhen Salubris Pharmaceuticals Co., Ltd. It details updates to the issuance plan, including fundraising amounts, project investment, approval procedures, and risk disclosures. The document is relatively short (1252 characters) and serves as a public notice of changes to a capital raising plan rather than the full detailed report or financial statements. It does not contain comprehensive financial data or results but focuses on capital issuance updates and procedural information. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2021-01-20 Chinese
关于非公开发行股票申请文件二次反馈意见回复修订的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Shenzhen Xilintai Pharmaceutical Co., Ltd. regarding the revision and public disclosure of their response to the China Securities Regulatory Commission's (CSRC) second feedback on their non-public issuance of A shares application. It mentions the submission of reply materials to the CSRC and the ongoing approval process. The document is short (849 characters) and primarily serves as an announcement of the filing and regulatory feedback process rather than containing detailed financial data or the actual application documents. It does not contain financial statements or detailed report content but is an update on regulatory review and disclosure obligations. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2021-01-20 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.